Evaluation of the Therapeutic Effect of HU Pulse Therapy for CML Patients
Status:
Unknown status
Trial end date:
2020-05-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chronic-phase chronic myelogenous leukemia (CML) aimed to avoid CML
conversion (AP, BC). Hydroxyurea pulse therapy for chronic-phase CML patients is effective
based on the investigator's previous studies, and the scheme cost lower than imatinib. It is
not yet known the efficacy compared Hydroxyurea pulse therapy with imatinib for chronic-phase
CML, especially to achieve hematological remission in short time.
PURPOSE: Non-randomized trial to compare the effectiveness of hydroxyurea pulse therapy with
that of imatinib in treating chronic-phase CML patients.
Phase:
Phase 3
Details
Lead Sponsor:
First Affiliated Hospital of Harbin Medical University